The re-treatment of patients with recurrent prostate cancer after initial, first-line treatment for what was initially diagnosed as localized disease can be complicated. Success (i.e., effective re-treatment with curative intent) in the re-treatment of such patients is often dependent on the ability to identify exactly where recurrence has occurred. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: gallium-68, PET, PSMA, radio-guided, recurrent, scan, surgery | 3 Comments »
Data from a small, randomized, Phase II, clinical trial have suggested a possible role for bevacizumab (Avastin) in the treatment of men with recurrent prostate cancer along with androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, Avastin, bevacizumab, deprivation, outcome, recurrent | Leave a comment »
A small Phase I clinical trial in just 36 patients, funded by the Mushroom Growers of Australia and North America, has suggested that powdered mushroom may have an effect on PSA levels of at least some men with recurrent prostate cancer after first-line therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: mushroom, outcome, powder, recurrent, Treatment | 6 Comments »
A report in the Journal of Nuclear Medicine suggests that gallium-68 PSMA (68Ga-PSMA or [68Ga]PSMA) is better than an older radionuclide in detecting recurrent lesions in men with progressive prostate cancer after first-line therapy with surgery or radiation therapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: detect, gallium-68, locate, PSMA, radionuclide, recurrent | 6 Comments »
Inovio Pharmaceuticals is initiating a Phase I trial of INO-5150 — a new type of immunotherapy for prostate cancer which targets both the prostate-specific antigen (PSA) and the and the prostate specific membrane antigen (PSMA). … READ MORE …
Filed under: Drugs in development | Tagged: INO-5150, Inovio, Phase I, recurrent, trial | Leave a comment »
The advent of imaging tests like the [11C]choline PET/CT scan and others have made it possible to identify, relatively early, the presence of one or more foci of recurrent prostate cancer after first-line therapy, and often these recurrent foci can be found in patients’ pelvic lymph nodes. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: choline, lymph node, PET/CT, positive, recurrent, salvage, Treatment | 10 Comments »
An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: imaging, progressive, recurrent | 1 Comment »
A newly published, retrospective, epidemiological study has looked at the potential role of metformin the the management of prostate cancer in > 350 men already diagnosed and being treated for diabetes in the Shared Equal Access Regional Cancer Hospital (SEARCH) database. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Uncategorized | Tagged: metformin, progressive, recurrent | 1 Comment »
Data have been emerging for a while to suggest that a new imaging agent known as anti-3-[18F]FACBC (when used in PET/CT scans may be better than [11C]choline in the identification of recurrent (or primary) cancers on PET/CT scans or than older agents like [111In]capromab pendetide (Prostascint) when used in SPECT/CT scans. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: anti-3-[18F]FACBC, imaging, PET/CT, recurrent, scan | 4 Comments »
A study presented this week at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver compares [11C]choline-enhanced PET/CT and PET/MRI scanning in men with recurrent prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: PET/CT, PET/MRI, recurrent, restaging, scan | 10 Comments »
There were two posters presented at the Genitourinary Cancers Symposium regarding the use of “natural” agents in the management of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: acai, mushroom, PSA, recurrent | 7 Comments »
The U.S. Food & Drug Administration (FDA), yesterday, approved an imaging agent known as Choline C11 Injection for “production and use” to detect recurrent prostate cancer in men receiving positron emission tomongraphy or PET scanning. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: C11, choline, PET, recurrent, scan | 22 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 